Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?
Johnson & Johnson (NYSE: JNJ) won't be breathing down Intuitive Surgical's (NASDAQ: ISRG) neck anytime soon. But for the first time ever, the robotic surgery company has a serious competitor planning to encroach on its territory. With J&J's plans to produce a robotic surgical unit in full swing, a competitive showdown is now inevitable, and it'll play out over the rest of the decade.
But which business will prevail, and how much does it matter to investors? The stakes are quite high for Intuitive, so let's evaluate what's going on.
On Nov. 7, Johnson & Johnson announced that it would petition the Food and Drug Administration (FDA) in the second half of 2024 to get permission to start clinical trials for its surgical robotics system called Ottava. The four-armed robot will have a small footprint in the operating room, with the aim of cleanly integrating into a variety of surgical work routines. It isn't the company's first foray into the surgical robotics space, as it also makes another system intended for bronchoscopies, but the new entrant appears to be somewhat closer to a generalist tool rather than a highly specialized one.
Source Fool.com
